These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30735158)

  • 1. High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing.
    Khoury G; Purcell DFJ
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30735158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Molecular Biology of HIV Latency.
    Khoury G; Darcis G; Lee MY; Bouchat S; Van Driessche B; Purcell DFJ; Van Lint C
    Adv Exp Med Biol; 2018; 1075():187-212. PubMed ID: 30030794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
    Timmons A; Fray E; Kumar M; Wu F; Dai W; Bullen CK; Kim P; Hetzel C; Yang C; Beg S; Lai J; Pomerantz JL; Yukl SA; Siliciano JD; Siliciano RF
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15763-15771. PubMed ID: 32571938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
    Darcis G; Bouchat S; Kula A; Van Driessche B; Delacourt N; Vanhulle C; Avettand-Fenoel V; De Wit S; Rohr O; Rouzioux C; Van Lint C
    AIDS; 2017 Jan; 31(2):181-189. PubMed ID: 27755105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.
    Ke R; Conway JM; Margolis DM; Perelson AS
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of Latency as Part of a Cure for HIV-1.
    Rasmussen TA; Tolstrup M; Søgaard OS
    Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
    Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
    PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad activation of latent HIV-1 in vivo.
    Barton K; Hiener B; Winckelmann A; Rasmussen TA; Shao W; Byth K; Lanfear R; Solomon A; McMahon J; Harrington S; Buzon M; Lichterfeld M; Denton PW; Olesen R; Østergaard L; Tolstrup M; Lewin SR; Søgaard OS; Palmer S
    Nat Commun; 2016 Sep; 7():12731. PubMed ID: 27605062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
    Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
    Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro.
    Zerbato JM; Serrao E; Lenzi G; Kim B; Ambrose Z; Watkins SC; Engelman AN; Sluis-Cremer N
    J Virol; 2016 Sep; 90(18):8059-73. PubMed ID: 27356901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.